The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Related Articles
Mount Sinai Researchers Uncover Why Some Leukemia Cells May Resist Treatment
Research from the Icahn School of Medicine at Mount Sinai provides new insights into acute myeloid leukemia (AML) and its resistance to a common treatment.
The Targeted Pulse: Looking Back at 2024’s Achievements and Exploring Potential Approvals on The Horizon
In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. Advances also included December approvals,…
In APL, 2 targets are better than 1!
In this issue of Blood, Voso et al1 present an analysis of long-term outcomes for 1438 patients with acute promyelocytic leukemia (APL). Their data, accumu
Olutasidenib alone or in combination with azacitidine in patients with IDH1-mutated MDS
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, comments on the safety and efficacy of olutasidenib alone or in combination with azacitidine in…
Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC
Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.
What To Know About Lung Cancer in Nonsmokers
Without a doubt, smoking is the No. 1 cause of lung cancer. But as many as 15% of men and 50% of women who are…
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repai…
Chances of quitting smoking improve with integrated care, including medication and counseling
Smokers undergoing lung cancer screening may have the best chance of quitting if they receive integrated care, which includes medication and comprehensive counseling with tobacco…
Survey Dangerous gap in knowledge about pancreatic cancer among adults under age 50
While pancreatic cancer rates are rising in people under age 50, a new survey conducted by the OSUCCC – James shows most people continue to…
Dato-DXd Receives FDA Priority Review in Pretreated EGFR-Mutated NSCLC
The BLA for Dato-DXd in locally advanced or metastatic EGFR-mutated NSCLC has been accepted and granted priority review by the FDA.